Fatostatin inhibits SREBP2-mediated cholesterol uptake via LDLR against selective estrogen receptor α modulator-induced hepatic lipid accumulation
- 6 August 2022
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 365, 110091
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Estrogen Receptors and the Metabolic NetworkCell Metabolism, 2011
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2011
- Four decades of discovery in breast cancer research and treatment an interview with V. Craig JordanThe International Journal of Developmental Biology, 2011
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamstersJournal of Lipid Research, 2010
- Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liverJournal of Lipid Research, 2006
- Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosisThe FASEB Journal, 2005
- Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipidsBreast Cancer Research and Treatment, 2004
- Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatinCardiovascular Research, 2004
- Crucial Step in Cholesterol HomeostasisCell, 2002
- Receptor-Mediated Control of Cholesterol MetabolismScience, 1976